Arcutis Biotherapeutics News

Arcutis Biotherapeutics CFO Sells Shares Worth Over $110,000

InvestingSep 25 21:46 ET

Analysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI) and Arcutis Biotherapeutics (ARQT)

TipRanksSep 25 07:50 ET · Ratings

Express News | New Data Shows Zoryve® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types

ReutersSep 25 01:00 ET

New Data Shows ZORYVE (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types

GlobeNewswireSep 25 01:00 ET

Express News | Arcutis Biotherapeutics Inc - FDA Sets Pdufa Target Action Date of May 22, 2025

ReutersSep 24 08:00 ET

Express News | FDA Accepts Arcutis’ Supplemental New Drug Application for Zoryve® (Roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over

ReutersSep 24 08:00 ET

FDA Accepts Arcutis' Supplemental New Drug Application for ZORYVE (Roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over

GlobeNewswireSep 24 08:00 ET

Express News | Arcutis Announces Publication of Zoryve® (Roflumilast) Cream 0.15% Pivotal Results From Phase 3 Integument-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology

ReutersSep 19 08:00 ET

Arcutis Announces Publication of ZORYVE (Roflumilast) Cream 0.15% Pivotal Results From Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology

GlobeNewswireSep 19 08:00 ET

Morgan Stanley Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $19

Moomoo NewsSep 19 06:33 ET · Ratings

Buy Rating Affirmed for Arcutis Biotherapeutics Amid Positive Dermatology Market Signals

TipRanksSep 19 06:17 ET · Ratings

Rock Star Growth Puts Arcutis Biotherapeutics (NASDAQ:ARQT) In A Position To Use Debt

Simply Wall StSep 8 09:50 ET

Insider Selling: Director Howard Welgus Sells 10,000 Shares of Arcutis Biotherapeutics Inc (ARQT)

InvestingSep 5 19:29 ET

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswireSep 5 16:00 ET

Express News | Arcutis Completes Enrollment of Phase 1B Alopecia Areata Study Evaluating Arq-255

ReutersSep 5 08:01 ET

Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255

GlobeNewswireSep 5 08:00 ET

Arcutis Biotherapeutics, Inc. (ARQT): This Small-Cap Healthcare Stock Is A Good Buy Right Now

Yahoo FinanceSep 5 00:01 ET

Express News | Arcutis Biotherapeutics Inc -No New Safety Signals Observed During 56 Weeks of Treatment

ReutersAug 28 08:02 ET

Express News | Arcutis Biotherapeutics Inc: To Submit Snda to U.S. FDA in Q1 2025 for Roflumilast Cream 0.05%

ReutersAug 28 08:01 ET

Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 With Mild to Moderate Atopic Dermatitis

GlobeNewswireAug 28 08:00 ET